Mohammad Aldiabat, MD, MPH
@DrDiabat
Followers
963
Following
5K
Media
52
Statuses
395
Instructor @WashUMedicine | Alum @HarvardChanSPH, @NYULangone, @NYCHealthSystem, @JUSTEDUJO
St Louis, MO
Joined May 2010
Excited to share our latest study in BMJ Open on the relationship between MASLD/MASH and the risk of colorectal cancer and benign colorectal neoplasms 💥💥 Thanks to the stellar team @SLUgastro @washumedicine & @MahMadi90 @MalekAyoubMD 🌟👏🏼 https://t.co/QjYc4I5Aik
3
2
5
Our recent publication in Clinical and Translational Gastroenterology highlights the impact of MASLD on autoimmune hepatitis outcomes. Grateful to collaborate with the outstanding team @SLUgastro on this piece! @YasKL88 @MahMadi90 @SLUgastro
#epidemiology #GITwitter
Our latest publication 🚨 "The Impact of MASLD on Autoimmune Hepatitis Outcomes: A Nationwide Analysis of 2880 Records" In AIH patients, MASLD was linked to: ⬇️ 1-yr immunosuppressant use (HR 0.69) ⬆️ 10-yr risk of cirrhosis (HR 1.22) ⬆️ 10-yr risk of HCC (HR 2.03) 👉
0
0
8
Excited to share our new study in Digestive Diseases & Sciences! 📊 BCAA supplements in cirrhosis = better outcomes 💥 Most benefit observed in viral & alcohol associated cirrhosis. 🔗 https://t.co/b7OcdEAxep Grateful to the amazing team @SLUgastro! #GITwitter
2
3
24
🎓 NOW ACCEPTING APPLICATIONS 🔬 Advanced IBD Fellowship July 1, 2026 – June 30, 2027 @WashUMedGastro @WashUMedIBD Specialized, hands-on experience in Inflammatory Bowel Disease care, research, innovation. 📷📩 ibdfellowship@wustl.edu 🔗 https://t.co/4Rh6WdEm56 📷 @WashUMedIBD
ibd.wustl.edu
The mission of the WashU Medicine Comprehensive IBD Center of Excellence is to improve quality-of-life for IBD patients regionally and globally through an interdisciplinary approach that integrates...
2
12
34
Congrats to all the #ACG2025 awardees! Your tweets bring back great memories from #ACG2022. See you all in Phoenix this October! @AmCollegeGastro #GITwitter
0
1
40
🔥 Hot off the press! Check out our latest study in The American Journal of the Medical Sciences: ↑ Risk of Vibrio vulnificus in MASLD, cirrhosis & CLD https://t.co/9Fq266f7bu Thanks to the amazing team @SLUgastro, @DDCMUSC, @UCIrvine 🌟 @MahMadi90 @YasKL88
2
4
20
What memorable days! ✨ Today, I close a chapter I once only dreamed of—MPH in Epidemiology from @Harvard 🎓 Grateful for the journey, the mentors, the prayers, the struggles, and every quiet sacrifice. Grateful. Humbled. Ready 🙏🌹 @HarvardChanSPH #Classof2025
8
3
48
NYC ↔️ Boston ↔️ St. Louis From the wards 🏥 to the classroom 📚 —Back and forth, but always forward! 💥 Grateful for 2 years of growth and learning 🙏 Thanks @HarvardChanSPH @HarvardEpi @Harvard for sharing a piece of the journey 🎓 📜 🌟
4
1
48
Grateful to present, connect & learn from incredible minds in the GI community. This @DDWMeeting: 12 abstracts 8 as 1st author 1 oral, 7 poster presentations 9/12 manuscripts written/submitted Huge thanks to @P_DeepakIBDMD , @WashUMedGastro & @SLUgastro! Excited for what ahead!
2
1
36
Glad to see our RWE on RZB vs UST in bio-naive CD fueling discussion around real-world treatment trends. @P_DeepakIBDMD @EdwardLoftus2 @AndresYarur @JeanFredericCo1 @WashUMedGastro @WashUMedIBD
Very large RWE study from USA comparing effectiveness of risankizumab versus ustekinumab in bionaive Crohn's disease Retrospective TriNetX US collaborative network (total 118m individual) • Adult CD patients from June 2022 to October 2024 • After propensity matching 1562
0
2
5
Highlighting our findings on RZB vs UST outcomes in bio-naive Crohn’s at @DDWMeeting
@P_DeepakIBDMD @EdwardLoftus2 @AndresYarur @JeanFredericCo1 @WashUMedGastro @WashUMedIBD
Risankizumab and USTK had similar outcomes at 1 and 2 years in bionaive #crohns patients in admin database study by Aldiabat et al. #DDW2025 #IBD
0
1
8